证券代码：600223 证券简称：福瑞达 编号：临 2025-026 鲁商福瑞达医药股份有限公司 第十二届董事会 2025 年第三次临时会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 鲁商福瑞达医药股份有限公司第十二届董事会2025年第三次临时会议于 2025年9月14日发出通知，并于2025年9月19日以通讯方式召开。本次董事会由董 事长贾庆文先生召集，应参会董事5名，实际参加表决的董事5名，同时监事会成 员审阅了本次会议的议案，符合《公司法》和公司章程规定。 经参会董事审议表决，全票通过以下议案并形成如下决议： 一、全票通过《关于续聘会计师事务所的议案》，公司拟续聘上会会计师事 务所（特殊普通合伙）为公司2025年度财务及内控审计机构。该议案已经公司董 事会审计委员会审议通过，尚需提交公司股东会审议。具体内容详见《鲁商福瑞 达医药股份有限公司关于续聘会计师事务所的公告》（临2025-027）。 二、全票通过《关于召开公司 2025 年第一次临时股东会的议案》，公司定 于 2025 年 10 月 10 日 ...

Company Overview - Furida (SH 600223) announced the convening of its 2025 third temporary board meeting on September 19, 2025, via communication methods, where it reviewed the proposal for the reappointment of the accounting firm [1] Financial Performance - For the first half of 2025, Furida's revenue composition was as follows: cosmetics accounted for 61.13%, property leasing for 16.37%, pharmaceuticals for 11.57%, additives for 9.98%, and other businesses for 0.95% [1] - As of the report date, Furida's market capitalization was 7.8 billion yuan [1]

Core Viewpoint - The stock of Furuida has experienced fluctuations, with a recent decline in price and significant net outflow of funds, indicating potential investor concerns about the company's performance and market position [1][2]. Financial Performance - Furuida's stock price has increased by 3.33% year-to-date, but has seen declines of 3.37% over the last five trading days, 9.57% over the last 20 days, and 6.17% over the last 60 days [2]. - For the first half of 2025, Furuida reported revenue of 1.79 billion yuan, a year-on-year decrease of 7.05%, and a net profit attributable to shareholders of 108 million yuan, down 15.16% year-on-year [2]. Shareholder Information - As of June 30, 2025, Furuida had 47,500 shareholders, an increase of 8.26% from the previous period, with an average of 21,396 circulating shares per shareholder, a decrease of 7.63% [2]. - The company has distributed a total of 1.196 billion yuan in dividends since its A-share listing, with 213 million yuan distributed over the last three years [3]. Market Activity - Furuida has appeared on the "Dragon and Tiger List" once this year, with the most recent appearance on June 11, where it recorded a net buy of -9.7777 million yuan [2]. - The company's main business segments include cosmetics (61.13%), property management and others (16.37%), pharmaceuticals (11.57%), and raw materials and derivatives (9.98%) [2]. Institutional Holdings - As of June 30, 2025, Hong Kong Central Clearing Limited was the ninth largest circulating shareholder, holding 4.8242 million shares, a decrease of 1.4592 million shares from the previous period [3]. - The Southern CSI 1000 ETF (512100) entered as the tenth largest circulating shareholder, holding 472,070 shares [3].

Group 1 - The Chinese beauty products industry is accelerating its "going global" strategy, with exports of cosmetics and personal care products expected to reach 51.2 billion RMB in 2024, a year-on-year increase of 11.9% [1] - Incorporating Chinese culture into brand building is seen as an effective strategy for establishing brand recognition in overseas markets, with companies like Plant Doctor Group using traditional Chinese medicinal ingredients to attract consumers [1][2] - The rise of Chinese cultural influence is enhancing the appeal of domestic beauty brands in international markets, as brands that integrate cultural elements into their narratives can build unique recognition [2][3] Group 2 - Localized design strategies are crucial for Chinese beauty brands to succeed in diverse international markets, as consumer preferences vary significantly across regions [4][5] - Companies like Orange Group are focusing on understanding overseas market preferences and adapting their products accordingly, including developing new shades and formulations to meet local needs [4][5] - Establishing local teams and R&D centers abroad helps brands better align with market demands and regulatory standards, enhancing consumer trust and product freshness [5][6] Group 3 - Continuous investment in technological innovation is strengthening the competitive edge of Chinese beauty products in the global market, with companies developing proprietary technologies and establishing comprehensive supply chains [6][7] - The industry is witnessing a shift towards technology-driven growth, with brands increasingly focusing on R&D to create effective products that meet consumer needs [7][8] - The next 3 to 5 years are expected to see an intensified effort from Chinese beauty brands to expand internationally, particularly in emerging markets, facilitated by the growth of cross-border e-commerce [8]

Market Overview - On September 16, the cosmetics sector rose by 0.03% compared to the previous trading day, with Shuiyang Co., Ltd. leading the gains [1] - The Shanghai Composite Index closed at 3861.87, up 0.04%, while the Shenzhen Component Index closed at 13063.97, up 0.45% [1] Individual Stock Performance - Shuiyang Co., Ltd. (300740) closed at 22.48, with a gain of 1.63% and a trading volume of 208,500 shares, amounting to a transaction value of 469 million yuan [1] - Qingdao Kingway (002094) closed at 8.47, up 1.44%, with a trading volume of 326,600 shares and a transaction value of 277 million yuan [1] - Other notable performers include: - Kezhou Co., Ltd. (300856) at 14.23, up 0.57% [1] - Beitaini (300957) at 49.13, up 0.41% [1] - Furuida (600223) at 7.91, up 0.38% [1] Fund Flow Analysis - The cosmetics sector experienced a net outflow of 43.2 million yuan from institutional investors, while retail investors saw a net outflow of 23.0 million yuan [2] - Conversely, speculative funds recorded a net inflow of 66.2 million yuan [2] Detailed Fund Flow for Key Stocks - Shuiyang Co., Ltd. (300740) had a net inflow of 41.1 million yuan from institutional investors, while retail investors faced a net outflow of 71.8 million yuan [3] - Qingdao Kingway (002094) saw a net inflow of 15.3 million yuan from institutional investors, but a net outflow of 7.2 million yuan from retail investors [3] - Other stocks with significant fund flow include: - Beitaini (300957) with a net inflow of 5.7 million yuan from institutional investors and a net outflow of 13.2 million yuan from retail investors [3] - Furuida (600223) faced a net outflow of 10.2 million yuan from institutional investors but a net inflow of 8.9 million yuan from retail investors [3]

Market Overview - On September 15, the cosmetics sector declined by 0.18%, with Huaye Fragrance leading the drop [1] - The Shanghai Composite Index closed at 3860.5, down 0.26%, while the Shenzhen Component Index closed at 13005.77, up 0.63% [1] Individual Stock Performance - Notable gainers included: - Jinsong New Material (300849) with a closing price of 14.48, up 3.72% and a trading volume of 121,800 shares, totaling 179 million yuan [1] - Lafang Home (603630) closed at 28.58, up 2.11% with a trading volume of 71,300 shares, totaling 200 million yuan [1] - Notable decliners included: - Huaye Fragrance (300886) closed at 29.66, down 1.79% with a trading volume of 18,400 shares, totaling 55.05 million yuan [2] - Marubi Biological (603983) closed at 39.95, down 1.36% with a trading volume of 13,900 shares, totaling 55.49 million yuan [2] Capital Flow Analysis - The cosmetics sector experienced a net outflow of 83.38 million yuan from institutional investors, while retail investors saw a net inflow of 76.42 million yuan [2] - The overall capital flow for individual stocks showed: - Jinsong New Material had a net inflow of 18.50 million yuan from institutional investors, accounting for 10.31% of its total [3] - Huaye Fragrance had a net outflow of 4.23 million yuan from institutional investors, accounting for 6.58% of its total [3]

Investment Rating - The report initiates coverage with a "Buy" rating for Shuiyang Co., Ltd. [3][13] Core Insights - The cosmetics and medical beauty sector underperformed the market, with the Shenwan Beauty Care Index increasing by 0.2% from September 5 to September 12, 2025, lagging behind the Shenwan A Index by 2.7 percentage points [3][4] - Domestic cosmetics brands showed strong growth in August, with key brands under Shumei Co. achieving a 70% growth rate on Douyin and Taobao platforms, indicating a robust performance despite high base effects [3][9] - The report highlights the upcoming Double 11 shopping festival, suggesting that brands should prepare for promotional strategies [3][9] Summary by Sections Industry Performance - The cosmetics and medical beauty sector's performance was weaker than the market, with declines in the Shenwan Cosmetics Index by 0.5% and the Shenwan Personal Care Index by 0.8% during the specified period [3][4] Key Company Review - Shuiyang Co., Ltd. is positioned as a leading technology-driven beauty company in China, with stable revenue between 4 to 5 billion yuan from 2021 to 2024 and an expected gross margin of 63.01% in 2024, up by 10.94 percentage points from 2021 [3][10] - The company has a dual business model of proprietary brands and CP agency brands, with a strong focus on high-end and global market transformation [3][10][12] E-commerce Data - In August, key domestic brands on Douyin and Taobao platforms showed significant growth, with Shumei Co. brands achieving a 70% increase, and other brands like Maogeping and Runben also reporting substantial growth rates [3][14] Market Trends - The report notes that the overall retail sales of cosmetics in July 2025 grew by 4.5%, indicating a recovery in consumer spending [3][17] - The domestic skincare market is projected to reach 271.2 billion yuan in 2024, despite a slight decline of 3.7% year-on-year, with domestic brands gaining market share [3][26] Company Announcements - Shumei Co. has appointed Dr. Karl Lintner, a pioneer in peptide beauty, as the chief scientific advisor, aiming to enhance its global competitiveness in research and development [3][21]

Investment Rating - The investment rating for the company is "Buy" and is maintained [7] Core Views - The company reported a revenue of 1.79 billion yuan for H1 2025, a year-on-year decline of 7.05%, and a net profit attributable to shareholders of 110 million yuan, down 15.2% year-on-year [2][4] - In Q2 alone, the company achieved a revenue of 910 million yuan, a decrease of 11.7% year-on-year, with a net profit of 57.25 million yuan, down 16.1% year-on-year [2][4] - The cosmetics business, particularly the Yilian brand, showed steady growth, while the Aier Doctor brand is undergoing a phase of adjustment [10] Summary by Sections Financial Performance - For H1 2025, the cosmetics, pharmaceutical, and raw materials segments generated revenues of 1.09 billion, 210 million, and 180 million yuan respectively, with year-on-year changes of -7.7%, -13.9%, and +4.2% [10] - The Yilian brand achieved a revenue of 550 million yuan, a growth of 23.8% year-on-year, while the Aier Doctor brand saw a revenue decline of 30% to 450 million yuan [10] - The overall gross profit margin slightly improved, with a net profit margin of 6%, down 0.6 percentage points year-on-year [10] Business Segments - The Yilian brand's growth was supported by the announcement of a global spokesperson, leading to a 43% increase in the spray product line [10] - The Aier Doctor brand is in a brand adjustment phase, with new product launches expected to drive future growth [10] - The raw materials business showed stability, with sales of hyaluronic acid reaching 120 million yuan, a year-on-year increase of 23.4% [10] Future Outlook - The company is expected to focus on its main brands, with the Yilian brand showing strong momentum and the Aier Doctor brand undergoing necessary adjustments [10] - The company anticipates improvements in profitability due to optimized channel structures and enhanced gross margins in the raw materials segment [10] - EPS forecasts for 2025-2027 are projected at 0.24, 0.29, and 0.34 yuan per share respectively [10]

Core Viewpoint - The skincare and daily chemical industry in A-share listed companies has shown significant performance divergence in the first half of 2025, with 14 representative companies analyzed for their financial results [1]. Group 1: Performance Analysis - Six companies experienced declines in both revenue and net profit: Lafang Jiahua, Furuida, Fulejia, Beitaini, Huaxi Biological, and Kesi Co. [1] - Lafang Jiahua reported revenue of 410 million yuan, a decrease of 4.27% year-on-year, and a net profit of 6 million yuan, down 82.89% compared to the previous year [1]. - Furuida achieved revenue of 1.79 billion yuan, a decline of 7.05% year-on-year, with a net profit of 108 million yuan [1]. - One company, Chuang'er Biological, saw revenue growth of 16.98% to 214 million yuan but a net profit decline of 55.99% to 13 million yuan [1]. - Jiaheng Jiahua reported revenue of 514 million yuan, an increase of 21.72% year-on-year, but a net loss of 32 million yuan, with losses widening compared to the previous year [1]. Group 2: Factors Influencing Performance - Jiaheng Jiahua's significant net loss is closely linked to its Huzhou base, with new business expansions impacting operational performance [2]. - Lafang Jiahua's dual decline in performance is attributed to changes in the domestic and international operating environment, compounded by intensified industry competition, despite increased market investment [2].

Group 1 - The cosmetics sector experienced a slight increase of 0.22% on September 10, with Jinsheng New Materials leading the gains [1] - The Shanghai Composite Index closed at 3812.22, up 0.13%, while the Shenzhen Component Index closed at 12557.68, up 0.38% [1] - Jinsheng New Materials saw a significant rise in its closing price to 14.38, reflecting an increase of 11.73% with a trading volume of 139,700 shares and a transaction value of 198 million yuan [1] Group 2 - The cosmetics sector faced a net outflow of 10.99 million yuan from institutional investors and 78.76 million yuan from retail investors, while individual investors saw a net inflow of 89.75 million yuan [2] - The trading data indicates that Jinsheng New Materials had a net inflow of 24.75 million yuan from institutional investors, despite a net outflow from retail and speculative investors [3] - Qingdao Kingway and Beitaini also reported net inflows from retail investors, while other companies like Shanghai Jahwa and Marubi experienced net outflows from both institutional and speculative investors [3]